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Background: Although COPD exacerbations are known to occur more frequently in winter, 
there is little information on hospitalizations and cause-specific mortality. This study aimed to 
examine seasonal variations in mortality and exacerbations in patients with COPD during the 
TIOtropium Safety and Performance In Respimat® (TIOSPIR®) trial.
Patients and methods: TIOSPIR was a large-scale, multicenter trial, which assessed the 
safety and efficacy of tiotropium delivered via HandiHaler® (18 μg once daily) or Respimat® Soft 
Mist™ (2.5 or 5 μg once daily) inhaler in patients with COPD. Patients were aged $40 years, 
with a smoking history $10 pack-years, and post-bronchodilator forced expiratory volume in 
1 second #70% and forced expiratory volume in 1 second/forced vital capacity #0.70. COPD 
exacerbations and deaths were monitored throughout the trial. The data were pooled to examine 
seasonal patterns. Southern hemisphere data were shifted by 6 months to align with northern 
hemisphere seasons.
Results: TIOSPIR was conducted in 43 northern (n=15,968) and 7 southern (n=1,148) hemisphere 
(n=1,148) countries. The median duration of treatment was 835 days, with a mean follow-up 
of 2.3 years. Among 19,494 exacerbations, there were clear seasonal differences (winter, 6,646 
[34.1%]; spring, 4,515 [23.2%]; summer, 3,198 [16.4%]; autumn, 5,135 [26.3%]). Exacerba-
tions peaked in early winter (December in the northern hemisphere and June in the southern 
hemisphere), respiratory hospitalizations in midwinter, and respiratory deaths in early spring.
Conclusion: Although winter poses a 2-fold hazard for COPD exacerbations vs summer, respi-
ratory deaths peak in early spring. These data suggest that seasonal intensification of preventive 
treatments may impact COPD morbidity and mortality.
Trial registration number: NCT01126437.
Keywords: TIOSPIR, tiotropium, HandiHaler, Respimat Soft Mist inhaler, seasonality, 
preventive treatment, exacerbations
Plain language summary
In this retrospective substudy, we analyzed data from the large-scale, multicenter TIOSPIR 
clinical trial to study seasonal patterns in the numbers and severity of COPD symptom “flare-
ups”, cause-specific deaths, and major adverse cardiac events in over 17,000 patients with COPD 
residing in 50 countries. The study was conducted in both the northern and southern hemispheres, 
and the southern hemisphere data were shifted by 6 months to align with the northern hemisphere 
seasons. The data collected confirm the results of COPD symptom “flare-ups” noted from other 
large clinical trials and provide new data on seasonal variation in cardiovascular and respiratory 
cause-specific death rates. Winter was associated with a 2-fold increase in COPD symptom 
severity compared with summer; however, the peak of respiratory-related deaths occurred in 
early spring, suggesting that recurrent COPD “flare-ups” or subsequent pneumonia accounts 
for peak respiratory death rates. Seasonal intensification of preventive therapy may reduce both 
the severity of COPD symptoms and death rates.
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Introduction
In the general population, seasonal differences in mortality 
have been observed, with more people dying in winter.1–4 
Seasonal variations have been shown for several clinical 
conditions, where symptoms and mortality increase in 
winter, for example, cardiovascular disease,2,5–7 influenza 
and pneumonia,8–10 and pulmonary embolism.11–13 COPD 
exacerbations,14 COPD-related hospitalizations,15 commu-
nity-acquired pneumonia,16 and respiratory mortality are 
also most common in winter,14,17–20 and may be influenced 
by increased incidence of infections. Acute exacerbations of 
COPD etiology vary with season, and the rises in incidence 
in winter may be driven by increased airway infections.21
Understanding the nature and magnitude of seasonal dif-
ferences for COPD morbidity is important as it can: 1) guide 
efficient health resource allocation; 2) suggest seasonal 
strategies to prevent exacerbations in high-risk patients; 
and 3) assist in efficient planning of clinical trials studying 
COPD exacerbations.
Seasonal differences in the occurrence of COPD exacer-
bations have been found in several clinical trials.18,19 These 
differences were most evident in the northern hemisphere, 
but prospectively collected data on seasonal variations in 
hospitalization, cause-specific mortality, and major adverse 
cardiac events (MACE) have yet to be reported.
Analyzing the largest long-term trial in COPD (TIOtropium 
Safety and Performance In Respimat [TIOSPIR®]) reported 
to date22,23 provided a unique opportunity to expand our 
understanding of seasonal variations in COPD morbidity 
and mortality. TIOSPIR was conducted worldwide in the 
northern and southern hemispheres, involving 1,202 centers in 
50 countries. It had an almost complete follow-up vital status 
rate (99.7% of randomized patients); exacerbation events 
were monitored and verified, underlying causes of death 
adjudicated, and MACE data collected. Compared to other 
clinical studies, TIOSPIR used liberal inclusion and exclu-
sion criteria, especially regarding concomitant cardiovascular 
diseases. Thus, the TIOSPIR data allowed us to study the 
effect of seasonality on the numbers and severity of exac-
erbations, cause-specific mortality, and MACE in a broadly 
representative COPD population of sufficient size to examine 
less-frequent events and provide estimates of the magnitude 
of any seasonal effect on important COPD outcomes.
Patients and methods
study design
The main trial design and rationale have been described 
previously.22 Briefly, TIOSPIR was a randomized, multicenter, 
double-blind, parallel-group, event-driven trial designed to 
assess safety and efficacy of tiotropium delivered once daily 
via HandiHaler® (18 μg) or Respimat® (2.5 or 5 μg) inhaler 
in COPD patients.
TIOSPIR was conducted in compliance with the Dec-
laration of Helsinki. The study protocol and procedures 
were approved by the local institutional review boards and 
ethics committees for participating centers (Table S1). All 
patients gave written informed consent prior to participation 
in the study.
study participants
Patients were outpatients, aged $40 years, who were either 
current or ex-smokers with $10 pack-years of smoking 
history. Patients had a COPD diagnosis, post-bronchodilator 
forced expiratory volume in 1 second #70% predicted, and 
post-bronchodilator forced expiratory volume in 1 second/
forced vital capacity #70%. Complete inclusion/exclusion 
criteria are provided in Table S2. Maintenance respiratory 
medications and medications for comorbid conditions were 
permitted, with the exception that non-study drug inhaled 
anticholinergics were not permitted.
assessments
The co-primary end points for the main trial were times 
to all-cause death and first COPD exacerbation. Outcome 
measures evaluated for this analysis included number and 
incidence of moderate-to-severe COPD exacerbations, severe 
COPD exacerbations, cause-specific deaths, and MACE. 
MACE included fatal events in the Medical Dictionary for 
Regulatory Activities V.16.0 system organ classes of cardiac 
and vascular disorders; outcome events (serious and nonseri-
ous) of myocardial infarction, stroke, and transient ischemic 
attack; and preferred terms of sudden death, cardiac death, 
and sudden cardiac death. Sudden death was death occur-
ring .1 to ,24 hours from a patient being last seen alive 
without an evident deteriorating medical condition. Sudden 
cardiac death was a marked change in a patient’s clinical 
state resulting in death within 1 hour of onset in the absence 
of noncardiac causes.
Exacerbations were defined as increase or new onset 
of $2 lower respiratory symptoms (breath shortness, sputum 
production, purulent sputum, cough, wheezing, and chest 
tightness) that were COPD related, lasted $3 days, and 
required a treatment change (antibiotics and/or systemic 
steroids prescription, or new respiratory medication). Exac-
erbations were classified as mild (requiring new maintenance 
bronchodilator only), moderate (requiring antibiotics or sys-
temic steroids without hospitalization), and severe (requiring 
hospitalization). Exacerbation onset was defined as the first 
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recorded symptom, and exacerbation end was based on a 
site-investigator report. When there were ,7 days between 
the end of one exacerbation and the beginning of another, 
they were combined into a single exacerbation (if the first 
exacerbation was pretreatment, it was not combined).
An independent Mortality Adjudication Committee 
blinded to treatment reviewed the case report forms, medical 
documents, and witness reports and adjudicated the primary 
underlying cause of death using standardized criteria.24,25 
Generally, primary death cause was attributed to the under-
lying clinical condition for which the patient initially pre-
sented for treatment and not to the immediate cause of death 
(further details are provided in the Supplementary Appendix 
of Wise et al23). Respiratory deaths were defined as those 
in the “Respiratory, thoracic, and mediastinal disorders” 
system organ classes, along with deaths from respiratory 
tract infections.
All patients, including those who discontinued the study 
drug early, were followed for vital status until the end of the 
trial. Patients discontinuing early had a 30-day follow-up, 
and thereafter, were followed for vital status every 12 weeks 
until the end of the trial.
statistical analyses
Deaths (all-cause and cause-specific) and COPD exacerba-
tions were described numerically and by incidence rates 
using descriptive statistics.
Death rates were calculated from the vital status set 
(full follow-up period) and exacerbation rates from the treated 
set (on-treatment period), accounting for time at risk and 
treatment duration, respectively. Incidence rates were based 
on 1,000 patient-months’ exposure.
To study seasonal patterns, data from the treatment groups 
were pooled.23 To compare northern and southern hemisphere 
data, southern hemisphere data were shifted by 6 months 
(eg, for the first winter month, December in the northern 
hemisphere aligned to June in the southern hemisphere).
Results
Baseline demographics and characteristics
Of 20,313 patients screened for TIOSPIR, 17,183 were ran-
domized and 17,135 (99.7%) received $1 dose of study med-
ication (vital status data set). The treated data set comprised 
17,116 patients, since 19 were excluded for data irregularities. 
In the northern hemisphere, 15,987 patients were in the vital 
status data set and 15,968 in the treated data set, while in 
the southern hemisphere the vital status and treated data 
sets both had 1,148 patients. Study centers (N=1,202) were 
located in 43 northern and 7 southern hemisphere countries 
(Table 1). The median duration of treatment was 835 days 
(range 1–1,027 days), with a mean follow-up of 2.3 years.
Patient baseline and clinical characteristics were rela-
tively well balanced between the hemispheres (Table 1). 
The only notable differences between the northern and 
southern hemispheres were that in the northern hemisphere 
a higher proportion of patients were current smokers (39.0% 
Table 1 Baseline demographic and clinical characteristics of 
patients from the northern and southern hemispheres
Variable Northern 
hemispherea 
(n=15,968)
Southern 
hemisphereb 
(n=1,148)
Sex
Male 11,426 (71.6) 811 (70.6)
Female 4,542 (28.4) 337 (29.4)
Race
White 12,939 (81.0) 1,024 (89.2)
Black 178 (1.1) 78 (6.8)
asian 2,383 (14.9) 45 (3.9)
Missing 468 (2.9)c 1 (0.1)d
Age, years 64.9±9.1 66.1±9.0
Age class, years
,60 4,476 (28.0) 287 (25.0)
60 to ,70 6,259 (39.2) 443 (38.6)
$70 5,233 (32.8) 418 (36.4)
Body mass index, kg/m2 26.3±5.7 25.6±5.2
Body mass index class
Underweight (,18.5 kg/m2) 1,013 (6.3) 85 (7.4)
normal (18.5 to ,25 kg/m2) 6,210 (38.9) 476 (41.5)
Pre obese (25 to ,30 kg/m2) 5,140 (32.2) 369 (32.1)
Obese ($30 kg/m2) 3,605 (22.6) 218 (19.0)
COPD duration, years 7.4±6.2e 7.7±5.9
Smokers
never smoked 3 (0.0) 0 (0.0)
ex-smoker 9,745 (61.0) 849 (74.0)
Current smoker 6,220 (39.0) 299 (26.0)
Smoking history, pack-years 43.3±24.3 50.1±29.2
Pulmonary medication
ICs (but not laBa) 1,034 (6.5) 197 (17.2)
laBa (but not ICs) 1,628 (10.2) 78 (6.8)
Both ICs and laBa 8,239 (51.6) 633 (55.1)
neither ICs nor laBa 5,067 (31.7) 240 (20.9)
Systolic blood pressure, mmHg 131.2±15.3f 127.9±15.4
Diastolic blood pressure, mmHg 78.1±9.6f 77.8±9.8
Pulse rate, bpm 76.8±11.7f 76.1±11.1
Region
europe, africa, australia, new Zealand 9,197 (57.6) 442 (38.5)
latin america 294 (1.8) 706 (61.5)
north america 4,121 (25.8) 0 (0.0)
asia 2,356 (14.8) 0 (0.0)
Notes: Data are expressed as mean ± sD or as number (%) patients. aForty-three 
northern hemisphere countries: austria, Belgium, Bulgaria, Canada, P.r. China, 
Croatia, Denmark, Finland, France, georgia, germany, greece, guatemala, hungary, 
India, Ireland, Israel, Italy, latvia, lithuania, Malaysia, Mexico, the netherlands, 
norway, Panamá, Philippines, Poland, Portugal, republic of Korea, romania, russia, 
serbia, slovakia, spain, sweden, switzerland, Taiwan r.O.C., Thailand, Tunisia, Turkey, 
Ukraine, UK, and Usa. bseven southern hemisphere countries: argentina, australia, 
Brazil, Colombia, new Zealand, Peru, and south africa. cThis category includes 
468 patients from France where race cannot be collected. dOne patient from Peru 
whose race was determined to be Mestizo. en=15,965 patients. fn=15,959 patients.
Abbreviations: ICs, inhaled corticosteroids; laBa, long-acting beta-agonist.
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vs 26.0%), a lower proportion were taking only inhaled 
corticosteroids (6.5% vs 17.2%), and a higher proportion 
were taking neither inhaled corticosteroids nor long-acting 
beta-agonists (31.7% vs 20.9%).
In the northern hemisphere, the mean ± SD exposure time 
to treatment was 731±257 days and the mean observation 
time was 842±142 days. In the southern hemisphere these 
were slightly lower, with a mean exposure of 683±241 days 
and a mean observation time of 778±167 days. These equated 
to overall observation times of 36,781 patient-years in the 
northern and 2,440 patient-years in the southern hemisphere. 
In both hemispheres, the proportion of patients with ,1 year 
of treatment was around 13%, so bias by season of recruit-
ment between the hemispheres is unlikely.
exacerbations
Overall, 8,342 (48.7%) patients had $1 exacerbation and 
2,506 (14.6%) had $1 severe exacerbation. Among the total 
19,494 exacerbations, the highest number (6,646 [34.1%]) 
occurred in winter and the lowest (3,198 [16.4%]) in summer. 
Severe exacerbations (3,816 [19.6% of all exacerbations]) 
followed the same pattern, with the highest frequency in 
winter (1,349 [35.4%]) and the lowest in summer (611 
[16.0%]). Mild exacerbations were rare, with 97.9% (19,093) 
of all exacerbations being moderate to severe.
For each hemisphere, the numbers of exacerbations and 
patients experiencing exacerbations are given in Table 2. 
The proportion of patients in the northern hemisphere who 
experienced $1 exacerbation requiring treatment was lower 
than in the southern hemisphere (48.0% vs 59.4%), whereas 
the proportions of patients experiencing severe exacerba-
tions requiring hospitalization were similar for the two 
hemispheres (14.6% vs 14.8%).
Figure 1 illustrates overall variations in exacerbations 
by month, adjusted for hemisphere. Overall, the number 
of exacerbations was highest in early winter and lowest in 
midsummer; hospitalized severe exacerbations were delayed 
by 1 month. Severe exacerbations peaked in midwinter and 
were lowest in late summer.
In the northern hemisphere, winter accounted for 
34.6% (6,147/17,742) and summer accounted for 15.8% 
(2,807/17,742) of all exacerbations. This difference was not 
as strong in the southern hemisphere, with 28.5% (499/1,752) 
of exacerbations in winter and 22.3% (391/1,752) in summer. 
In the northern hemisphere, 35.9% (1,280/3,563) of all severe 
exacerbations occurred in winter and 15.4% (547/3,563) in 
summer, whereas in the southern hemisphere, the propor-
tions were similar for winter (27.3% [69/253]) and summer 
(25.3% [64/253]).
Mean incidence of exacerbations for the northern hemi-
sphere was 1.65-fold higher in winter than in summer (53.6 
vs 32.5 per 1,000 patient-months), whereas in the southern 
hemisphere, it was 1.56-fold higher (83.0 vs 53.1 per 
1,000 patient-months). Similar differences in incidence were 
found for all severity categories of exacerbation, with winter 
rates ~2.0-fold greater in the winter peak than the summer nadir 
(Figure 1E; Table S3). Seasonal differences occurred during 
all three trial years, indicating that the results were not the 
consequence of a single severe winter (Figures S1 and S2).
all-cause deaths
Within the vital status observation period, 7.6% (1,302/17,135) 
of patients died – 7.3% (1,169/15,987) in the northern and 
11.6% (133/1,148) in the southern hemisphere. Overall, 
deaths were 1.6 times more frequent in winter (32.6% 
[424/1,302]) than summer (20.5% [267/1,302]).
The mean death rate (deaths per month as a percentage of 
total deaths during the study) and the incidence of all-cause 
deaths in the northern hemisphere were greatest in winter, 
peaking in midwinter and were lowest in early summer 
(Figure 2A and B, respectively). In the northern hemisphere, 
33.6% (393/1,169) of all-cause deaths occurred in winter and 
20.0% (234/1,169) in summer. In the southern hemisphere, 
a seasonal difference was not apparent for all-cause deaths, 
with the lowest mean value recorded in mid-spring and the 
Table 2 number of exacerbations and deaths for patients from 
the northern and southern hemispheres
Variable Northern 
hemisphere 
(n=15,968)
Southern 
hemisphere 
(n=1,148)
Total COPD exacerbations requiring 
treatment, n
17,742 1,752
Patients with $1 exacerbation, n (%) 7,660 (48.0) 682 (59.4)
Total moderate-to-severe COPD 
exacerbations, n
17,365 1,728
Patients with $1 moderate-to-severe 
exacerbation, n (%)
7,520 (47.1) 675 (58.8)
Total severe COPD exacerbations 
requiring hospitalization
3,563 253
Patients with $1 severe exacerbation 
requiring hospitalization, n (%)
2,336 (14.6) 170 (14.8)
Deaths, n (%)
all-cause 1,169 (7.3) 133 (11.6)
MaCe 299 34
neoplasms 284 21
respiratory 393 53
Other 193 25
Abbreviation: MaCe, major adverse cardiac event.
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Figure 1 numbers of exacerbations and incidence rates per 1,000 patient-months of exposure adjusted by hemisphere.
Note: (A) number of all exacerbations, (B) occurrence of first exacerbation, (C) number of all severe exacerbations, (D) occurrence of first severe exacerbation, and 
(E) exacerbation incidence rates.
Abbreviations: nh, northern hemisphere; sh, southern hemisphere.
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highest in late spring (Figure 2C and D); 23.3% (31/133) 
of all deaths occurred in winter and 24.8% (33/133) in 
summer. In the northern hemisphere, the mean incidence of 
all-cause deaths was 3.10 per 1,000 patient-months in winter 
and 2.41 per 1,000 patient-months in summer; equivalent 
values for the southern hemisphere were 4.69 and 4.10 per 
1,000 patient-months, respectively.
In the data set adjusted for hemisphere, a seasonal mortality 
difference was apparent, with the mean proportion and 
incidence of deaths peaking in midwinter (Figure 2E and F, 
respectively). The lowest proportion of deaths occurred in 
early summer and the lowest incidence was in early autumn. 
Data for individual months in each year are provided in 
Figure S3.
Cause-specific deaths
The number of deaths and the incidence rate per 1,000 
patient-months of exposure for cause-specific deaths (MACE, 
respiratory, neoplasms, and other causes) are presented in 
Figure 3. Overall, the most common cause of death was 
respiratory (34.3%, 0.99 per 1,000 patient-months), followed 
by MACE (25.6%, 0.77 per 1,000 patient-months) and neo-
plasms (23.4%, 0.72 per 1,000 patient-months); other causes 
accounted for 16.7% (0.61 per 1,000 patient-months). As a 
proportion of all respiratory deaths, 33.0% occurred in winter 
and 18.2% in summer. Respiratory deaths and incidence of 
respiratory deaths showed a marked seasonal pattern, peaking 
in early spring and reaching a nadir in midsummer. Although 
the number and incidence of deaths related to MACE peaked 
Figure 2 (Continued)
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in early winter and reached a nadir in early summer, a sea-
sonal effect was not as pronounced as for respiratory deaths. 
The number of deaths related to neoplasms and other causes 
also peaked in winter (early and midwinter, respectively), 
but seasonality was not pronounced.
Discussion
Our analysis shows marked seasonal variation in COPD 
exacerbations, hospitalization, and mortality. These results 
confirm the results of exacerbations noted from analyses of 
other studies15,16,18,19,21 and extend the findings to hospitaliza-
tion for exacerbations and respiratory mortality. Of interest, 
in the northern hemisphere, the peak for exacerbations is 
early winter, followed by the peak for hospitalizations in 
midwinter and for respiratory deaths in early spring. The 
reason that seasonal differences for these events are not 
aligned is not clear. We speculate that milder exacerbations 
in early winter may provide the substrate for later, more 
Figure 2 Mean frequency of all-cause deaths (per month as a percentage of the total deaths occurring over the study) and incidence rates of all-cause deaths per 
1,000 patient-months of exposure.
Note: (A) northern hemisphere: percentage of deaths, (B) northern hemisphere: incidence rate, (C) southern hemisphere: percentage of deaths, (D) southern hemisphere: 
incidence rate, (E) hemisphere adjusted percentage of deaths, and (F) hemisphere adjusted incidence rate.
Abbreviations: nh, northern hemisphere; sh, southern hemisphere.
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Figure 3 Mean numbers and incidence rates per 1,000 patient-months of exposure for cause-specific deaths adjusted for hemisphere.
Note: (A) number of MaCe-related deaths, (B) incidence rate of MaCe-related deaths, (C) number of respiratory-related deaths, (D) incidence rate of respiratory-related 
deaths, (E) number of neoplasm-related deaths, (F) incidence rate of neoplasm-related deaths, (G) number of other-related deaths, (H) incidence rate of other-related deaths.
Abbreviations: MaCe, major adverse cardiac event; nh, northern hemisphere; sh, southern hemisphere.
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severe, exacerbations and that these events are the substrate 
for subsequent mortality. In this regard, it has been shown 
that COPD exacerbations tend to be clustered and occur with 
increasing frequency over time.26,27 Moreover, our results 
are consistent with the finding of Suissa et al27 who report 
that mortality peaks in the 8 weeks after a severe COPD 
exacerbation.
We also compared seasonal variations in the northern and 
southern hemispheres. In the northern hemisphere, more than 
twice as many COPD exacerbations occurred in winter than 
in summer (representing 34.6% and 15.8%, respectively, of 
all exacerbations). In the southern hemisphere, there was a 
27.6% increase in exacerbations in winter vs summer, with 
28.5% of all exacerbations occurring in winter and 22.3% in 
summer. This disparity may reflect differences in health care 
systems impacting time to patient presentation and admission 
or, since most of the southern hemisphere countries are near 
the equator, there may have been fewer seasonal variations 
in weather in these mostly tropical countries compared with 
those in the northern hemisphere; for example, Colombia 
and Brazil are equatorial and, therefore, may lack seasons. 
It is also possible that tropical regions are subject to different 
types of infections or other exposures that are not present in 
the northern hemisphere.
Two other large multinational trials, Toward a Revolution 
in COPD Health (TORCH)18 and Prevention of Exacerbations 
with Tiotropium in COPD (POET-COPD),19 also examined 
seasonal variations in deaths and exacerbations in COPD. 
A comparison of the characteristics and results of these trials 
together with those of TIOSPIR is provided in Table S4.
Our findings from TIOSPIR are somewhat different 
from those of TORCH,18 a global clinical trial involving 
6,112 patients in 42 countries (northern region, n=4,849; 
southern region, n=622; and tropics, n=641). In TORCH, 
seasonal exacerbation patterns were seen in both southern 
and northern regions, peaking in winter and reaching a nadir 
in summer, whereas the tropical region showed no seasonal 
patterns. Based on the percentage of patients with exacerba-
tions, there was a 1.8-fold increase in exacerbations in winter 
compared with summer in the northern region and a 1.7-fold 
increase in the southern region. In our analysis, we did not 
separate out the tropical region, which may account for the 
different findings.
The POET-COPD trial19 was conducted only in the 
northern hemisphere and included 7,376 COPD patients, 
of whom 2,691 reported exacerbations. Exacerbation rates in 
POET-COPD showed a seasonal pattern, peaking in winter, 
with a mean monthly exacerbation rate of 7.63 exacerbations 
per 100 patient-months, which was 2.16-fold higher than the 
mean summer rate of 3.53 exacerbations per 100 patient-
months. In TIOSPIR, the mean monthly exacerbation rate for 
the northern hemisphere was 1.65-fold higher in winter than 
in summer, with exacerbation rates per 100 patient-months of 
5.36 and 3.25 for winter and summer, respectively. Greater 
seasonality and higher event rates in POET-COPD likely 
reflected the different enrollment criteria for that trial, which 
sought out patients with high exacerbation risk.
In TIOSPIR, the proportion of all exacerbations requiring 
hospitalization was 19.6%, which is remarkably similar to 
the overall figure of 20% reported by TORCH.18 In POET-
COPD,19 the proportions of all exacerbations that were severe 
were similar for winter and summer (15.8% vs 17.3%); our 
data for the northern hemisphere are similar, with the pro-
portions of all exacerbations that were severe being 20.8% 
for winter and 19.5% for summer. Thus, it does not appear 
that increased hospitalizations and mortality in winter are 
caused by a shift in the severity of exacerbations, but are due 
to increase in the overall number of events.
In TIOSPIR, in the northern hemisphere, 33.6% of all 
deaths occurred in winter and 20.0% in summer. These 
findings are similar to those of TORCH,18 where 29% of 
deaths occurred in winter and 22% in summer, and of POET-
COPD,19 where 34.5% of deaths occurred in winter and 
13.4% in summer. In TIOSPIR, in the southern hemisphere, 
a strong seasonal difference was not apparent, with 23.3% 
of all deaths occurring in winter and 24.8% in summer; in 
TORCH, in the southern region, 37% of all deaths occurred 
in winter and 14% in summer. In TIOSPIR, in the northern 
hemisphere, the mean incidence rate of all deaths was 
3.10 per 1,000 patient-months for winter, which is higher 
than in POET-COPD, that is, 2.28 per 1,000 patient-months. 
The TIOSPIR summer death rate of 2.41 per 1,000 patient-
months was also substantially higher than that of POET-
COPD (0.88 per 1,000 patient-months). It seems paradoxical 
that POET-COPD had a higher exacerbation rate, yet lower 
death rate, compared with TIOSPIR. We speculate that the 
lower death rates in POET-COPD were due to a combina-
tion of lower mean patient age (63±9 years) compared with 
TIOSPIR (65±9 years) and differences in follow-up of 1 vs 
2–3 years.
In TIOSPIR, the most common cause of death was 
respiratory (34.3%, 0.99 per 1,000 patient-months), which 
was lower than that reported by TORCH18 for COPD-related 
deaths (41%). This difference may be due to the presence of 
a placebo group in TORCH, whereas all patients in TIOSPIR 
were provided with maintenance therapy. In TIOSPIR, 
numbers and incidence rates for respiratory-related deaths 
showed marked seasonality, peaking in early spring and 
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reaching a nadir in midsummer. Of all respiratory deaths, 
33.0% occurred in winter and 18.2% in summer; these figures 
are similar to those reported by TORCH for the northern 
region (34% and 20%, respectively), but not for the southern 
region (55% and 8%, respectively). In TIOSPIR, although 
the number and incidence of MACE-related deaths peaked in 
early winter and reached a nadir in early summer, a seasonal 
effect was not as evident as with respiratory deaths. MACE-
related deaths, which included sudden deaths, also showed a 
peak in early winter and a nadir in summer, but the seasonal 
difference was not as pronounced as for respiratory mortal-
ity, which, along with showing a peak in early spring, also 
demonstrated a second peak in late summer. The cause of this 
late summer peak is not known; however, it may reflect higher 
levels of air pollutants, warmer temperatures, or cyclical 
variation in aeroallergens or respiratory viral infections.
The study’s strengths are that it reports seasonality data 
from a large-scale multicenter trial spanning the northern 
and southern hemispheres, including 17,116 patients who 
reported 19,494 exacerbations. Vital status follow-up was 
high (99.7% of randomized patients), and causes of deaths 
were adjudicated to a primary cause by an independent 
Mortality Adjudication Committee, rather than via death 
certificates, which may underestimate respiratory deaths.28 
MACE was included as a secondary outcome and was moni-
tored and classified prospectively according to predefined 
criteria. In contrast to trials that enroll patients at high risk 
for exacerbation, the inclusion and exclusion criteria were 
designed to include a broad COPD population, reflecting 
patients that physicians encounter in daily practice.29
The study has some limitations. Although generally, 
patients with comorbidities, including those with history 
of cardiac disorders, were included in the trial, those with 
unstable cardiovascular conditions or moderate-to-severe 
renal impairment were excluded. The diagnosis of COPD 
exacerbation was made based on clinical grounds; however, 
we cannot exclude the possibility that other conditions, such 
as decompensated heart failure or pulmonary embolism, 
may have contributed to the respiratory decompensation 
events. All patients were on maintenance therapy for COPD 
with $1 long-acting bronchodilator during the trial, which 
may have reduced the overall exacerbation rate compared 
with the general COPD population.30 Data on influenza and 
pneumococcal immunization were not included as part of 
the trial, so we cannot determine if these measures altered 
the winter peak of respiratory illness and deaths. Seasonal 
variability to COPD exacerbations may reflect different 
etiologies, such as exposure to air pollution, allergens, viral 
infections, or bacterial infections. However, we are unable to 
determine, from this data set, whether this is the case. Finally, 
because the trial was dominated by data from the northern 
hemisphere (93.7% of all data), and we did not classify the 
sites by weather patterns, our findings regarding lack of 
seasonality in the southern hemisphere must be interpreted 
with some caution. The allocation of countries to the northern 
and southern hemispheres was based on their relationship 
to the equator; Brazil and Colombia cross the equator, but 
were included in the southern hemisphere. Almagro et al15 
found that mean temperatures and COPD-related hospi-
talization are closely and independently related. Within 
each hemisphere, there are regional variations in seasonal 
temperature changes, both within and between countries; in 
our study, the groupings required to give the study enough 
power to identify an effect preclude the detailed analysis of 
temperature differences.
Our data raise a number of issues. First, the striking 
increase in winter morbidity and mortality suggests that 
physicians, health care systems, and policymakers could 
have a greater impact on the major complications of COPD 
by focusing on preventive measures before and during 
winter. Measures such as crowd avoidance, hand hygiene, 
and covering coughs could be stressed as part of individual 
COPD action plans, in conjunction with autumn influenza 
immunization campaigns. Second, staffing and facility 
resource allocation should take into account the 2-fold 
increases in COPD illness during winter. Third, our find-
ings stress the need for a full year’s data to assess the effects 
of policy and procedural interventions aimed at reducing 
COPD exacerbations and hospitalization rates; otherwise, 
seasonal differences may be interpreted as effects of these 
interventions. Fourth, clinical research aimed at evaluating 
or treating COPD exacerbations can leverage the striking 
seasonal variation to conduct more efficient research during 
winter. Finally, individual physicians may choose to initiate 
or intensify treatments aimed at reducing exacerbations in 
high-risk patients during autumn and winter. Our data sug-
gest that focused application of relatively simple measures 
to prevent early winter exacerbations might have an impact 
on subsequent hospitalizations and death.31
Conclusion
Patients and clinicians should be fully aware of the increased 
risks of COPD exacerbations and deaths in winter, to enable 
appropriate management strategies to be implemented. 
Clinical trials focusing on COPD exacerbations would be 
most efficiently conducted during winter.
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